BE2019C008I2 - - Google Patents

Download PDF

Info

Publication number
BE2019C008I2
BE2019C008I2 BE2019C008C BE2019C008C BE2019C008I2 BE 2019C008 I2 BE2019C008 I2 BE 2019C008I2 BE 2019C008 C BE2019C008 C BE 2019C008C BE 2019C008 C BE2019C008 C BE 2019C008C BE 2019C008 I2 BE2019C008 I2 BE 2019C008I2
Authority
BE
Belgium
Prior art keywords
compound
acetylaminoisoindoline
methylsulfonylethyl
dione
solvate
Prior art date
Application number
BE2019C008C
Other languages
Dutch (nl)
Original Assignee
Amgen Europe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28457137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2019C008(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Europe Gmbh filed Critical Amgen Europe Gmbh
Publication of BE2019C008I2 publication Critical patent/BE2019C008I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Discussed is stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable polymorph, salt, solvate or hydrate thereof, as well as a pharmaceutical composition or single unit dosage form comprising such compound and such compound for use as a medicine.
BE2019C008C 2002-03-20 2019-06-18 BE2019C008I2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36651502P 2002-03-20 2002-03-20
US43845003P 2003-01-07 2003-01-07
PCT/US2003/008738 WO2003080049A1 (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
EP03721414A EP1485087B1 (en) 2002-03-20 2003-03-20 (+)-2- [1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione for use in treating psoriasis by oral administration
EP09003138.6A EP2074995B1 (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof

Publications (1)

Publication Number Publication Date
BE2019C008I2 true BE2019C008I2 (en) 2022-08-09

Family

ID=28457137

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2019C008C BE2019C008I2 (en) 2002-03-20 2019-06-18

Country Status (24)

Country Link
US (14) US6962940B2 (en)
EP (9) EP2074995B1 (en)
JP (4) JP2005525386A (en)
KR (6) KR101263786B1 (en)
CN (2) CN100427085C (en)
AT (1) ATE440599T1 (en)
AU (1) AU2003224729C9 (en)
BE (1) BE2019C008I2 (en)
CA (2) CA2479666C (en)
CY (6) CY1109380T1 (en)
DE (1) DE60328974D1 (en)
DK (6) DK2295055T3 (en)
ES (8) ES2742729T3 (en)
FR (1) FR19C1046I2 (en)
HK (3) HK1073426A1 (en)
HU (5) HUE034348T2 (en)
IL (3) IL164147A0 (en)
LU (1) LUC00125I2 (en)
MX (2) MXPA04009075A (en)
NL (1) NL300994I2 (en)
NZ (1) NZ535798A (en)
PT (6) PT2295055T (en)
SI (5) SI2223687T1 (en)
WO (1) WO2003080049A1 (en)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0918746B1 (en) * 1996-08-12 2003-04-09 Celgene Corporation Immunotherapeutic agents and their use in the reduction of cytokine levels
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) * 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CA2379887C (en) * 2002-04-09 2004-01-20 Bernard Charles Sherman Stable tablets comprising simvastatin
CA2486141A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
ZA200503024B (en) * 2002-10-15 2006-11-29 Celgene Corp Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
CA2505003A1 (en) * 2002-11-06 2004-05-27 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
AU2003294312A1 (en) * 2002-11-18 2004-07-09 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CA2506232A1 (en) * 2002-11-18 2004-06-03 Celgene Corporation Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
ZA200507322B (en) * 2003-03-06 2007-03-28 Celgene Corp Selective cytokine inhibitory drugs for treating disorders of the central nervous system
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
WO2004087148A1 (en) * 2003-03-31 2004-10-14 Kyowa Hakko Kogyo Co. Ltd. Remedy and/or preventive for lung diseases
CA2543132A1 (en) * 2003-10-23 2005-05-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
WO2005046594A2 (en) * 2003-11-06 2005-05-26 Celgene Corporation Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
JPWO2005056009A1 (en) * 2003-12-12 2007-07-05 協和醗酵工業株式会社 Lung disease treatment
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
CN1984663A (en) 2004-03-29 2007-06-20 南佛罗里达大学 Effective treatment of tumors and cancer with triciribine and related compounds
US20100028339A1 (en) * 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
JP2007532642A (en) * 2004-04-14 2007-11-15 セルジーン・コーポレーション Use of selective cytokine inhibitors for the treatment and management of myelodysplastic syndromes and compositions containing the same
KR20070007945A (en) * 2004-04-23 2007-01-16 셀진 코포레이션 Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
EP1746989A4 (en) * 2004-05-05 2009-07-29 Celgene Corp Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
GB0410103D0 (en) * 2004-05-06 2004-06-09 Biolipox Ab New method
WO2005108353A2 (en) * 2004-05-06 2005-11-17 Ceptor Corporation Compounds for treating neurologic diseases, otologic diseases, or ophthalmologic diseases and methods of use thereof
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CN101111235A (en) * 2004-12-13 2008-01-23 细胞基因公司 Methods of using and compositions comprising pde4 modulators for treatment, prevention and management airway inflammation
CN102643267B (en) * 2005-06-30 2015-09-16 细胞基因公司 The preparation method of 4-amino-2-(2,6-dioxopiperidin-3-base) isoindoline-1,3-dione compounds
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
CN1870631B (en) * 2005-11-11 2010-04-14 华为技术有限公司 Gate control method of media gateway
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
US20080103086A1 (en) * 2006-10-25 2008-05-01 Jeon-Soo Shin Methods for the treatment of diseases associated with the secretion of hmgb1
TW200920381A (en) * 2007-07-17 2009-05-16 Combinatorx Inc Treatments of B-cell proliferative disorders
EP2178370A4 (en) * 2007-07-17 2011-01-12 Zalicus Inc Combinations for the treatment of b-cell proliferative disorders
US20090081173A1 (en) * 2007-08-10 2009-03-26 The Board Of Regents Of The University Of Texas System Methods and compositions involving bacteriophage isolates
CN102036663A (en) * 2008-03-24 2011-04-27 细胞基因公司 Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
KR20150038547A (en) 2008-03-27 2015-04-08 셀진 코포레이션 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CN102702070A (en) * 2008-03-27 2012-10-03 细胞基因公司 Solid form containing (+)-2-[1-(3-oxethyl-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, composition and application thereof
CN102898349A (en) * 2008-03-27 2013-01-30 细胞基因公司 Solid containing compound, a composition containing the solid and use of the solid
EP2687213B1 (en) 2008-03-27 2019-01-23 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US8053364B2 (en) * 2008-05-01 2011-11-08 Intermolecular, Inc. Closed-loop sputtering controlled to enhance electrical characteristics in deposited layer
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
WO2010025199A1 (en) * 2008-09-01 2010-03-04 Mitsubishi Digital Electronics America, Inc. Systems and methods to enhance television viewing
US20100186234A1 (en) * 2009-01-28 2010-07-29 Yehuda Binder Electric shaver with imaging capability
EA201171035A1 (en) 2009-02-10 2012-02-28 Селджин Корпорейшн COMPOSITIONS, INCLUDING MODULATORS PDE4, AND METHOD OF THEIR APPLICATION FOR THE TREATMENT, PREVENTION AND SUPPORT OF TUBERCULOSIS
US8952178B2 (en) 2009-05-14 2015-02-10 Tianjin Hemay Bio-Tech Co., Ltd. Thiophene derivatives
DK2456853T3 (en) * 2009-07-21 2021-02-01 Abt Holding Co USE OF STEM CELLS TO REDUCE LEUCOCYT EXTRAVASATION
CN102053448A (en) * 2009-10-28 2011-05-11 中国科学院福建物质结构研究所 Nitroaniline chiral non-linear optical material
CN102053449A (en) * 2009-10-28 2011-05-11 中国科学院福建物质结构研究所 Glutamic acid-derived chiral metal-organic nonlinear optical material
WO2011059931A2 (en) * 2009-11-10 2011-05-19 Celgene Corporation Nanosuspension of a poorly soluble drug via microfluidization process
MX341050B (en) 2010-04-07 2016-08-05 Celgene Corp * Methods for treating respiratory viral infection.
EP2583098B1 (en) 2010-06-15 2018-08-08 Celgene Corporation Biomarkers for the treatment of psoriasis
EP2651400B2 (en) 2010-12-16 2023-01-18 Amgen (Europe) GmbH Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2012083153A1 (en) * 2010-12-16 2012-06-21 Nektar Therapeutics Oligomer-containing apremilast moiety compounds
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2012096884A1 (en) * 2011-01-10 2012-07-19 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
CN103391770A (en) 2011-01-10 2013-11-13 细胞基因公司 Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
WO2012121988A2 (en) 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
WO2012149251A1 (en) 2011-04-28 2012-11-01 Celgene Corporation Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
SI2797581T1 (en) * 2011-12-27 2020-08-31 Amgen (Europe) GmbH Formulations of (+)-2-(1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl)-4-acetyl aminoisoindoline-1,3-dione
WO2013119607A2 (en) 2012-02-08 2013-08-15 Celgene Corporation Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
AR090100A1 (en) 2012-02-21 2014-10-22 Celgene Corp PROCESSES FOR THE PREPARATION OF (S) -1- (3-ETOXI-4-METOXIFENIL) -2-METHANOSULPHONILETILAMINE
US8981117B2 (en) 2012-09-14 2015-03-17 Celgene Corporation Processes for the preparation of isoindole compounds and isotopologues thereof
US20150290171A1 (en) * 2012-11-09 2015-10-15 Celgene Corporation Methods for the treatment of bone loss
CN105050624A (en) 2013-03-14 2015-11-11 细胞基因公司 Treatment of psoriatic arthritis using apremilast
US9468605B2 (en) * 2013-06-17 2016-10-18 Celgene Corporation Formulations of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
KR101561828B1 (en) 2013-08-23 2015-10-20 주식회사 아미노로직스 - Process for the racemization of -amino acids
EP3096749B1 (en) * 2014-01-24 2019-05-15 Celgene Corporation Methods for the treatment of obesity using apremilast
JP2014114308A (en) * 2014-01-31 2014-06-26 Celgene Corp Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CN103864670B (en) * 2014-03-17 2015-08-26 苏州明锐医药科技有限公司 The preparation method of A Pusite
IN2014MU01283A (en) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
WO2015173792A1 (en) 2014-05-11 2015-11-19 Mapi Pharma Ltd. Amorphous form of apremilast
PE20170280A1 (en) 2014-05-12 2017-03-30 Summit Mining Int Inc BRINE LEACHING PROCESS FOR THE RECOVERY OF VALUABLE METALS FROM OXIDE MATERIALS
WO2015175773A1 (en) 2014-05-15 2015-11-19 Celgene Corporation Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
WO2015175956A1 (en) 2014-05-16 2015-11-19 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
EP2949645A1 (en) 2014-05-28 2015-12-02 LEK Pharmaceuticals d.d. Processes for the preparation of ß-aminosulfone compounds
MX2016014384A (en) 2014-06-23 2017-01-20 Celgene Corp Apremilast for the treatment of a liver disease or a liver function abnormality.
CN105294534B (en) * 2014-07-15 2020-04-10 上海优拓医药科技有限公司 Industrialized method for preparing aplidine and intermediate thereof
EP3174999A1 (en) 2014-07-29 2017-06-07 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis
WO2016025686A1 (en) 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
CN105622380B (en) * 2014-10-29 2020-06-30 南京安源生物医药科技有限公司 Preparation method of apremilast and intermediate thereof
CN105588886B (en) * 2014-11-18 2020-01-31 重庆医药工业研究院有限责任公司 method for determining impurities in apremilast and its preparation by liquid chromatography
EP3034496A1 (en) * 2014-12-18 2016-06-22 LEK Pharmaceuticals d.d. Novel solvates of n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl]acetamide
CN104529869B (en) * 2014-12-19 2017-06-13 苏州亚宝药物研发有限公司 A kind of preparation method of (S) 2 [1 (methoxyphenyl of 3 ethyoxyl 4) 2 methylsulfonylethyls] diketone isomers of 4 acetylaminoisoindoline 1,3
WO2016135755A1 (en) 2015-02-27 2016-09-01 Mylan Laboratories Limited Amorphous apremilast, premixes thereof, and novel crystalline forms of apremilast
CN104803906A (en) * 2015-03-17 2015-07-29 南京新伟方医药科技有限公司 Compound as well as preparation method and application thereof
BR112017019850A2 (en) 2015-03-19 2018-06-05 Cipla Ltd Improved process for preparing apremilast
EP3280701B1 (en) 2015-04-09 2019-10-16 Zentiva K.S. A method of chiral resolution of the key intermediate of the synthesis of apremilast and its use for the preparation of pure apremilast
CN106146384B (en) * 2015-04-23 2020-09-22 石药集团中奇制药技术（石家庄）有限公司 Preparation method of high-optical-purity aplidine, obtained product and application thereof
WO2016169533A1 (en) 2015-04-24 2016-10-27 Zentiva, K.S. A solid form of apremilast and a process for preparing the same
US10370329B2 (en) * 2015-04-27 2019-08-06 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
CN104945306B (en) * 2015-05-25 2017-07-21 山东铭康医药技术有限公司 The method for preparing optical voidness Apremilast
JP2018516912A (en) * 2015-05-26 2018-06-28 ルピン・リミテッド Improved method of manufacturing apremilast and its novel polymorph
CZ2015383A3 (en) 2015-06-05 2016-12-14 Zentiva, K.S. Process for preparing apremilast key intermediate employing enzymatic cleavage of racemic amines
EP3106457A1 (en) 2015-06-15 2016-12-21 LEK Pharmaceuticals d.d. A novel synthetic pathway towards apremilast
CN105111127B (en) * 2015-08-20 2019-02-19 济南纽华医药科技有限公司 Apremilast is amorphous and preparation method thereof
US10494342B2 (en) 2015-08-26 2019-12-03 Glenmark Life Sciences Limited Process for the preparation of apremilast
US10544097B2 (en) 2015-08-27 2020-01-28 Msn Laboratories Private Limited Solid state forms of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide and process for preparation thereof
US9765026B2 (en) * 2015-08-28 2017-09-19 Scinopharm Taiwan, Ltd. Forms of apremilast and the process of making the same
EP3144393A1 (en) 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
WO2017059040A1 (en) * 2015-09-29 2017-04-06 Pliva Hrvatska D.O.O. Processes for the preparation of apremilast and intermediates thereof
CN105218428A (en) * 2015-10-20 2016-01-06 南京美嘉宁逸医药研究开发有限公司 A kind of preparation method of Apremilast of high chiral purity
US10682336B2 (en) 2015-10-21 2020-06-16 Amgen Inc. PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
EP3373916A1 (en) 2015-11-11 2018-09-19 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
US10399942B2 (en) 2015-11-19 2019-09-03 Alembic Pharmaceuticals Limited Process and novel polymorphic form of Apremilast
CN105348172B (en) * 2015-12-04 2017-11-14 新发药业有限公司 (S) preparation method of the preparation of the mesyl ethamine of 1 (ethyoxyl of 4 methoxyl group 3) phenyl 2 and Apremilast
EP3181549A1 (en) 2015-12-17 2017-06-21 Zaklady Farmaceutyczne Polpharma SA Process for the preparation of apremilast
CN105486785A (en) * 2015-12-23 2016-04-13 成都百裕金阁莱药业有限公司 Method for detecting enantiomer impurity in apremilast
CZ20165A3 (en) 2016-01-06 2017-07-19 Zentiva, K.S. A method of preparing amorphous apremilast
WO2017179065A1 (en) 2016-04-15 2017-10-19 Davuluri Ramamohan Rao Improved process for the preparation of apremilast
WO2017196192A1 (en) 2016-05-12 2017-11-16 Zaklady Farmaceutyczne Polpharma Sa Crystalline forms of apremilast
US20190175491A1 (en) 2016-06-15 2019-06-13 Torrent Pharmaceuticals Limited Topical compositions of apremilast
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
CN106187857B (en) 2016-06-30 2021-04-06 浙江华海药业股份有限公司 Method for preparing apremilast
IT201600083132A1 (en) * 2016-08-05 2018-02-05 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF AN INHIBITOR OF THE PHOSPHODIESTERASE 4
CN110049968A (en) * 2016-11-09 2019-07-23 广东东阳光药业有限公司 Apremilast eutectic and preparation method thereof
EP3339292A1 (en) 2016-12-23 2018-06-27 Zaklady Farmaceutyczne Polpharma SA Cocrystals of apremilast
AU2018213249A1 (en) * 2017-01-27 2019-09-19 Sarudbhava Formulations Private Limited Therapeutic topical compositions of Apremilast
CN107445875A (en) * 2017-03-22 2017-12-08 陕西科技大学 A kind of chiral separation method for being used to prepare the high-purity intermediate of Apremilast
HUE051684T2 (en) 2017-04-04 2021-03-29 Quim Sintetica S A Resolution of racemic beta-aminosulfone compounds
US10919855B2 (en) 2017-05-04 2021-02-16 Unichem Laboratories Ltd Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide
WO2019053612A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
CN107721902A (en) * 2017-11-08 2018-02-23 中国科学院上海药物研究所 Cocrystallization of Apremilast and niacinamide and its preparation method and application
CN111821299A (en) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 Use of thiophene derivatives for the treatment of immunoglobulin E (IgE) -mediated diseases
CN111821297A (en) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 Use of isoindoline derivatives for the treatment of immunoglobulin E (IgE) -mediated diseases
MX2021013317A (en) * 2019-04-30 2022-01-18 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors.
US11357775B2 (en) * 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
US11194866B2 (en) * 2019-08-08 2021-12-07 Google Llc Low entropy browsing history for content quasi-personalization
CN115766253A (en) 2019-08-08 2023-03-07 谷歌有限责任公司 Low entropy browsing history for content quasi-personalization
TWI733294B (en) 2019-12-30 2021-07-11 國立臺灣師範大學 Methods for preparation of apremilast
EP3929179A1 (en) 2020-06-22 2021-12-29 Biohorm, S.L. Anti-inflammatory compounds and methods for their manufacture
CN112220785B (en) * 2020-09-22 2021-12-31 北京鑫开元医药科技有限公司 PDE4 inhibitor pharmaceutical composition, preparation method and application thereof
KR20220047105A (en) 2020-10-08 2022-04-15 주식회사 엔비피헬스케어 Pharmaceutical composition containing apremilast
CN115068467A (en) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 Medical application of andrographolide as LTB4 receptor inhibitor
CN114790164B (en) 2021-08-13 2022-12-27 苏州璞正医药有限公司 Substituted isoindoline-1,3-diketone PDE4 inhibitor and pharmaceutical application thereof
EP4183389A1 (en) 2021-11-18 2023-05-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apremilast
WO2023105286A1 (en) 2021-12-06 2023-06-15 My Personal Therapeutics Ltd A combination treatment for cancer
WO2023121670A1 (en) * 2021-12-23 2023-06-29 Amgen Inc. Oral suspension of apremilast

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US366515A (en) 1887-07-12 Stove-pipe
US3031450A (en) * 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US3322755A (en) * 1964-03-10 1967-05-30 Boehringer Sohn Ingelheim Basic-substituted 1, 2, 3, 4-tetrahydropyrimido [5, 4-d]-pyrimidines
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS536156B2 (en) 1972-10-30 1978-03-04
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3820636A (en) * 1973-08-16 1974-06-28 Deere & Co Self-adjusting control linkage for an external band brake
US4162316A (en) * 1975-03-12 1979-07-24 Dainippon Pharmaceutical Co., Ltd. 1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives and compositions containing the same
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4001237A (en) * 1976-02-18 1977-01-04 Bristol-Myers Company Oxazole, isoxazole, thiazole and isothiazole amides
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
US4001238A (en) * 1976-02-18 1977-01-04 Bristol-Myers Company 1,3,4-oxadiazole amides
US4047404A (en) * 1976-11-17 1977-09-13 Tanno Senshoku Kogyo Co., Ltd. Printed fabric washing apparatus
US4101548A (en) * 1977-02-22 1978-07-18 Bristol-Myers Company 1,2,3-Thiadiazole amides
US4209623A (en) * 1978-06-07 1980-06-24 Bristol-Myers Company Pyrimidine-5-N-(1H-tetrazol-5-yl)-carboxamides
GB2063249A (en) 1979-10-09 1981-06-03 Mitsubishi Yuka Pharma 4-Phenylphthalazine derivatives
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4912205A (en) 1986-03-20 1990-03-27 Daicel Chemical Industries, Ltd. Alkyl-substituted phenylcarbamate derivative of polysaccharide
DE3770095D1 (en) * 1986-08-21 1991-06-20 Pfizer CHINAZOLINDIONE AND PYRIDOPYRIMIDINDIONE.
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
DE68908786T2 (en) 1988-06-16 1994-03-17 Smith Kline French Lab Condensed pyrimidine derivatives, processes and intermediates for their preparation and pharmaceutical preparations containing them.
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
GB8909560D0 (en) 1989-04-26 1989-06-14 Smith Kline French Lab Chemical compounds
GB8923131D0 (en) 1989-10-13 1989-11-29 Smith Kline French Lab Chemical compounds
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5401774A (en) * 1991-03-08 1995-03-28 University Of Arizona Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
PT100905A (en) 1991-09-30 1994-02-28 Eisai Co Ltd BICYCLE HYGIENEOUS HETEROCYCLIC COMPOUNDS CONTAINING BENZENE, CYCLOHEXAN OR PYRIDINE AND PYRIMIDINE, PYRIDINE OR IMIDAZOLE SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5354571A (en) * 1992-04-27 1994-10-11 Rheon Automatic Machinery Co., Ltd. Method for aligning and bending individual round elongated dough pieces
US5243826A (en) 1992-07-01 1993-09-14 Apd Cryogenics Inc. Method and apparatus for collecting liquid cryogen
JP2657760B2 (en) * 1992-07-15 1997-09-24 小野薬品工業株式会社 4-aminoquinazoline derivatives and pharmaceuticals containing them
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5614627A (en) * 1993-09-10 1997-03-25 Eisai Co., Ltd. Quinazoline compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5608914A (en) * 1994-11-21 1997-03-11 Keesler; Daren Headcover
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US5801195A (en) * 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
DE19501482A1 (en) 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituted purine-6-ones
DE19501480A1 (en) 1995-01-19 1996-07-25 Bayer Ag 9-substituted 2- (2-n-alkoxyphenyl) -purin-6-one
DE19501481A1 (en) 1995-01-19 1996-07-25 Bayer Ag 2,8-disubstituted quinazolinones
US5488055A (en) * 1995-03-10 1996-01-30 Sanofi Winthrop Inc. Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof
US5614530A (en) * 1995-03-10 1997-03-25 Sterling Winthrop Inc. Substituted N-arylmethyl and heterocyclmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines and compositions and methods of use thereof
EP0820441B1 (en) * 1995-04-10 2002-06-26 Fujisawa Pharmaceutical Co., Ltd. INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS
TW381092B (en) 1995-07-07 2000-02-01 Otsuka Pharma Co Ltd Novel benzimidazole derivatives for use in treating arteriosclerotic diseases
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5736537A (en) 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
US5658940A (en) * 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
DE19540475A1 (en) 1995-10-20 1997-04-24 Schering Ag Chiral methylphenyloxazolidinones
US5710170A (en) * 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
DK0882718T3 (en) 1995-12-28 2005-12-12 Astellas Pharma Inc benzimidazole
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
DE19617864A1 (en) * 1996-04-23 1997-10-30 Schering Ag New chiral phenyldihydrofuranones
DE19632423A1 (en) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidines
CA2236012A1 (en) 1996-08-30 1998-03-05 Koji Yamada Imidazoquinazoline derivatives
ATE229527T1 (en) 1996-10-04 2002-12-15 Kyorin Seiyaku Kk PYRAZOLOPYRIDYLPYRAZINONE DERIVATIVES AND A METHOD FOR THE PRODUCTION THEREOF
DE19642451A1 (en) 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophene carboxamides
DE19644228A1 (en) 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidines
KR100239800B1 (en) 1996-11-28 2000-03-02 손경식 4,5-diaminopyrimidine derivatives and its preparation
AU6230098A (en) 1997-02-27 1998-09-18 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
ES2302350T3 (en) * 1997-02-28 2008-07-01 Nycomed Gmbh SYNERGIC COMBINATION OF PDE INHIBITORS AND ADENYLATOCICLASS AGONISTS OR GUANILILCICLASA AGONISTS.
US6035089A (en) * 1997-06-11 2000-03-07 Lockheed Martin Energy Research Corporation Integrated narrowband optical filter based on embedded subwavelength resonant grating structures
HUP0003761A3 (en) 1997-07-31 2001-04-28 Celgene Corp Warren Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
US6020339A (en) * 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
US6034089A (en) * 1997-10-03 2000-03-07 Merck & Co., Inc. Aryl thiophene derivatives as PDE IV inhibitors
NZ502965A (en) * 1997-11-25 2002-03-01 Warner Lambert Co Benzenesulfonamide inhibitors of phosphodiesterase-IV for treating inflammation and TNF associated diseases
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6025394A (en) * 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
AU764005B2 (en) * 1999-02-25 2003-08-07 Merck Frosst Canada & Co. PDE IV inhibiting compounds, compositions and methods of treatment
US6316472B1 (en) * 1999-05-13 2001-11-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
SE9904415D0 (en) 1999-12-03 1999-12-03 Astra Ab New process
DE60018470T2 (en) * 1999-12-23 2006-02-16 Icos Corp., Bothell CYCLIC AMP SPECIFIC PHOSPHODIESTERASE INHIBITORS
PL357995A1 (en) 2000-01-31 2004-08-09 Pfizer Products Inc. Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7123975B2 (en) * 2004-07-22 2006-10-17 Taiwan Semiconductor Manufacturing Co., Ltd. Manufacturing management system and method
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US7838577B2 (en) 2007-07-19 2010-11-23 Sekisui Chemical Co., Ltd. Adhesive for electronic component
NZ587251A (en) 2008-01-18 2011-12-22 Oxagen Ltd Indole derivatives having CRTH2 antagonist activity
KR20150038547A (en) 2008-03-27 2015-04-08 셀진 코포레이션 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
MX2012004741A (en) 2009-11-19 2012-05-22 Celgene Corp Apremilast for the treatment of sarcoidosis.
WO2011151372A1 (en) 2010-06-02 2011-12-08 Ab Science Treatment of rheumatoid arthritis with masitinib

Also Published As

Publication number Publication date
KR20100040938A (en) 2010-04-21
AU2003224729A1 (en) 2003-10-08
US7659302B2 (en) 2010-02-09
SI2962690T1 (en) 2019-05-31
EP2223687B1 (en) 2017-05-17
ES2637547T3 (en) 2017-10-13
US8455536B2 (en) 2013-06-04
EP2311453B1 (en) 2017-06-07
CA2756798A1 (en) 2003-10-02
CY1119204T1 (en) 2018-02-14
PT2223688T (en) 2019-09-05
EP2962690A1 (en) 2016-01-06
US9283207B2 (en) 2016-03-15
US11260046B2 (en) 2022-03-01
KR20120024938A (en) 2012-03-14
HUE043539T2 (en) 2019-08-28
SI2223687T1 (en) 2017-10-30
KR100997001B1 (en) 2010-11-25
US20100160405A1 (en) 2010-06-24
ES2608495T3 (en) 2017-04-11
KR20050012722A (en) 2005-02-02
JP2010106033A (en) 2010-05-13
EP2295055B1 (en) 2017-06-07
PT1485087E (en) 2009-10-23
MXPA04009075A (en) 2005-07-13
KR101383845B1 (en) 2014-04-10
HUE029682T2 (en) 2017-02-28
EP2295055A2 (en) 2011-03-16
EP1485087B1 (en) 2009-08-26
ES2331991T3 (en) 2010-01-22
IL164147A0 (en) 2005-12-18
FR19C1046I2 (en) 2022-07-08
ES2635361T3 (en) 2017-10-03
HK1219049A1 (en) 2017-03-24
SI2295055T1 (en) 2017-10-30
JP5936521B2 (en) 2016-06-22
HK1073426A1 (en) 2005-10-07
DK2223688T3 (en) 2019-08-19
US20050192336A1 (en) 2005-09-01
CY2019032I1 (en) 2020-05-29
MX366328B (en) 2019-07-05
ES2717517T3 (en) 2019-06-21
EP2223688B1 (en) 2019-05-29
SI2223688T1 (en) 2019-11-29
LUC00125I1 (en) 2019-06-18
IL207149A (en) 2013-12-31
ATE440599T1 (en) 2009-09-15
CN1652772A (en) 2005-08-10
EP2295055A3 (en) 2011-03-23
CN101683334A (en) 2010-03-31
US20050267196A1 (en) 2005-12-01
CY1121720T1 (en) 2020-05-29
US20140371287A1 (en) 2014-12-18
PT2420490T (en) 2016-10-12
PT2223687T (en) 2017-07-25
HUE034348T2 (en) 2018-02-28
EP2311453A1 (en) 2011-04-20
ES2742729T3 (en) 2020-02-17
HUE045489T2 (en) 2019-12-30
DK2420490T3 (en) 2016-10-03
LUC00125I2 (en) 2019-12-24
EP2223688A1 (en) 2010-09-01
EP2074995B1 (en) 2016-11-02
US20170281597A1 (en) 2017-10-05
DK1485087T3 (en) 2009-11-02
NZ535798A (en) 2006-04-28
US20140024695A1 (en) 2014-01-23
US10092542B2 (en) 2018-10-09
EP2074995A1 (en) 2009-07-01
CY2019032I2 (en) 2020-05-29
US7427638B2 (en) 2008-09-23
CA2479666A1 (en) 2003-10-02
EP2420490B1 (en) 2016-07-20
PT2962690T (en) 2019-04-30
SI1485087T1 (en) 2009-12-31
US10610516B2 (en) 2020-04-07
HUS1900032I1 (en) 2019-07-29
AU2003224729B2 (en) 2008-01-03
KR101263786B1 (en) 2013-05-13
DE60328974D1 (en) 2009-10-08
US20210023051A1 (en) 2021-01-28
AU2003224729C1 (en) 2023-04-27
JP2015013893A (en) 2015-01-22
US20160151331A1 (en) 2016-06-02
PT2295055T (en) 2017-08-29
NL300994I2 (en) 2019-07-11
US11040024B2 (en) 2021-06-22
NL300994I1 (en) 2019-06-26
EP1485087A1 (en) 2004-12-15
US7507759B2 (en) 2009-03-24
US7358272B2 (en) 2008-04-15
EP2420490A1 (en) 2012-02-22
JP2013047262A (en) 2013-03-07
DK2295055T3 (en) 2017-09-11
US20200306226A1 (en) 2020-10-01
JP2005525386A (en) 2005-08-25
CY1109380T1 (en) 2014-07-02
EP3524242A1 (en) 2019-08-14
ES2595375T3 (en) 2016-12-29
WO2003080049A1 (en) 2003-10-02
US20190000804A1 (en) 2019-01-03
CY1121888T1 (en) 2020-10-14
KR20130040257A (en) 2013-04-23
KR20130100219A (en) 2013-09-09
US20030187052A1 (en) 2003-10-02
EP2223687A1 (en) 2010-09-01
CY1119340T1 (en) 2018-02-14
CA2479666C (en) 2012-01-10
AU2003224729C9 (en) 2023-06-15
US20080027123A1 (en) 2008-01-31
HK1103985A1 (en) 2008-01-04
KR20110022736A (en) 2011-03-07
DK2223687T3 (en) 2017-08-14
ES2637509T3 (en) 2017-10-13
US8802717B2 (en) 2014-08-12
US9724330B2 (en) 2017-08-08
US20080242719A1 (en) 2008-10-02
US20080207730A1 (en) 2008-08-28
FR19C1046I1 (en) 2019-08-09
KR101104991B1 (en) 2012-01-16
EP2962690B1 (en) 2019-01-16
US7659303B2 (en) 2010-02-09
US6962940B2 (en) 2005-11-08
IL164147A (en) 2010-11-30
DK2962690T3 (en) 2019-04-15
CN100427085C (en) 2008-10-22

Similar Documents

Publication Publication Date Title
BE2019C008I2 (en)
SI1487461T1 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
WO2005105088A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
MXPA05004778A (en) Methods of using and compositions comprising immunomudulatory compounds for the treatment and management of myeloproliferative diseases.
HRP20041092A2 (en) New pharmaceutical compositions containing filbanserin polymorph a
MXPA06003122A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist.
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
MXPA05010070A (en) Pharmaceutical combination comprising eletriptan and sodium bicarbonate.
MY137288A (en) New process for the synthesis of n-[(s)-1-ethoxycarbonylbutyl]-(s)-alanine and application in the synthesis of perindopril
MY137391A (en) New process for the synthesis of n-[(s)-1-ethoxycarbonylbutyl]-(s)-alanine and application in the synthesis of perindopril
TW200420560A (en) Crystalline form